NCT05076682View on ClinicalTrials.gov

Reverse Triple Negative Immune Resistant Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Triple-negative Breast Cancer
Interventions
DRUG

Choline

Choline 300mg tid or 500mg bid, p.o

DRUG

anti-PD-1 antibody and chemotherapy

PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

DRUG

Sodium Cromoglicate

Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)

DRUG

Efavirenz

Efavirenz 600mg qd, p.o

DRUG

SHR-A1811

4.8mg/kg q3w

DRUG

SHR-A2102

6mg/kg q3w

DRUG

SHR-1316

1200mg q3w

DRUG

Mecapegfilgrastim

Mecapegfilgrastim, 6mg, d3, q3w, s.c.

DRUG

AK131

AK131, 40mg/kg i.v., q2w

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER